Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial

Erstveröffentlichung
2020Authors
Kapp-Schwoerer, Silke
Weber, Daniela
Corbacioglu, Andrea
Gaidzik, I, Verena
Paschka, Peter
Wissenschaftlicher Artikel
Published in
Blood ; 136 (2020), 26. - S. 3041-3050. - ISSN 0006-4971. - eISSN 1528-0020
Link to publication
https://dx.doi.org/10.1182/blood.2020005998Institutions
UKU. Klinik für Innere Medizin IIISubject headings
[Free subject headings]: ACUTE MYELOID-LEUKEMIA | MINIMAL RESIDUAL DISEASE | POLYMERASE-CHAIN-REACTION | prognostic-significance | NPM1 | MUTATIONS | CLASSIFICATION | NUCLEOPHOSMIN | DIAGNOSIS[DDC subject group]: DDC 610 / Medicine & health